[의학신문·일간보사=김현기 기자] On the 16th, Humasys Co., Ltd. (CEO Jeong-hak Cha), a company specializing in rapid inspection, announced on the 16th that it had signed a 10 billion won treasury stock repurchase trust contract.
According to Humasys, this treasury share contract is for stock price stabilization and shareholder value enhancement.
CEO Cha Jeong-hak said, “This acquisition of treasury stock not only stabilizes the company’s stock price, but also builds confidence in the company’s continued growth potential as a leading company in the diagnostic kit market. “We plan to further lay the foundation for sustainable growth by expanding investments in various field diagnostics fields such as molecular diagnostics, biochemical diagnostics, and remote diagnostics,” he said.
In addition to the treasury stock repurchase trust contract, Humasys plans to make continuous efforts to improve shareholder-friendly policies and shareholder value, such as putting up a cash dividend agenda at the regular shareholders’ meeting to be held this month.
Meanwhile, Humasys recently obtained KGMP approval from the Ministry of Food and Drug Safety for a new manufacturing plant in Uiwang, Gyeonggi-do. We are producing a test quantity of COVID-19 rapid antigen diagnostic kits and self-test kits.
